Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization (Evolent/NCH review)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy requires review by Evolent (formerly New Century Health / NCH) for oncology medications and supportive agents (medical or pharmacy benefit) before dispensing or administration for Medicare - Wellcare by Fidelis Care members; it applies to participating providers and describes submission channels and scope/exclusions.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Evolent/NCH review)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateDec 1, 2024
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent (NCH) for review prior to dispensing or administration; omissions may result in denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All agesmember ages covered
    12/1/2024effective date for listed codes
    Numerous codesdrugs requiring review
    Listedbiosimilar preferences

    Coverage Criteria — Prior Authorization Requirements

    Prior authorization / clinical review requirement

    Covered when ALL of the following are met

    NCH review required: The oncology medication or supportive agent is submitted to and reviewed by Evolent (New Century Health) prior to dispensing at a pharmacy or administration in a physician's office, outpatient hospital, or ambulatory setting.

    Applies regardless of formulary status and to drugs listed by HCPCS/J/Q code in the document; submit the entire oncology regimen to Evolent (NCH); omissions may result in denial.

    Requests that should NOT be submitted to Evolent (New Century Health) for review include: Antibiotics; Bone marrow, stem cell transplants and CAR‑T cell therapy; Controlled substances (for example, morphine); equipment requests such as infusion pumps; genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    HCPCS / J / Q Codes and Pharmacy Codes Requiring Review

    Listed HCPCS/J/Q codes requiring review (sample)mixedCovered
    C9142BEVACIZUMAB-MALY.
    J0888
    C9169NOGAPENDEKIN ALFA INBAKICEPT-PMLN (ANKTIVA)
    J0893
    C9170TARLATAMAB-DLLE (IMDELLTRA)
    C9293GLUCARPIDASE
    J0185APREPITANT INJ
    J0881DARBEPOETIN ALFA NON-ESRD
    J0885EPOETIN ALFA NON-ESRD
    J2506PEGFILGRASTIM (ON-BODY INJECTOR) / PEGFILGRASTIM INJECTION
    1–10 of 16
    1/2
    Pharmacy benefit (oral) codes requiring reviewmixedCovered
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL
    J8530CYCLOPHOSPHAMIDE ORAL
    J8999Numerous oral oncology agents (example: ABEMACICLIB, ABIRATERONE ACETATE, ALECTINIB, etc.)
    HCPCS Q-codes and biosimilar product codesmixedCovered
    Q5116TRASTUZUMAB-QYYP
    Q5126BEVACIZUMAB-MALY
    Q5136DENOSUMAB-BBDZ (JUBBONTI, WYOST)

    What Providers Must Do

    Prior Authorization

    Prior authorization required for listed HCPCS/J/Q codes

    The oncology medications and supportive agents listed by HCPCS/J/Q code require review by Evolent (New Century Health) prior to dispensing or administration; this applies regardless of formulary status and includes items available via the medical or pharmacy benefit.

    • Applies to dispensing at a pharmacy or administration in a physician office, outpatient hospital, or ambulatory setting.
    • Includes the HCPCS/J/Q codes listed in the policy (examples shown in code tables).
    Step Therapy

    Biosimilar preference — submit preferred agents to NCH

    Preferred biosimilar agents are identified for certain oncology drug classes (e.g., erythropoiesis-stimulating agents, trastuzumab, bevacizumab, hematopoietic agents, rituximab); providers should still submit the chosen agent to NCH for review.

    • Erythropoiesis-stimulating agents: medical benefit Retacrit (Epogen if shortage); pharmacy benefit Procrit.

    Policy Background

    This policy centralizes clinical review of oncology medications and supportive agents through Evolent (formerly New Century Health) so that oncology‑related drug requests are evaluated for medical appropriateness prior to dispensing or administration. Participating providers must still submit preferred biosimilar agents when applicable; examples of preferred agents include Retacrit (medical benefit) with Epogen as the alternate if Retacrit is unavailable and Procrit for the pharmacy benefit for erythropoiesis‑stimulating agents, Trazimera (medical) and multiple trastuzumab products for pharmacy benefit, Mvasi and Zirabev for bevacizumab (medical) and Avastin, Mvasi, Zirabev for bevacizumab (pharmacy), and Zarxio for hematopoietic agents. Providers must continue to submit their chosen agents to NCH for review prior to dispensing/administration.

    Definitions and Scope

    Participating providers (definition and actions)
    DefinitionParticipating providers are those required to submit oncology medication and supportive agent requests to Evolent (formerly New Century Health, NCH) prior to dispensing at a pharmacy or administration in a physician office, outpatient hospital, or ambulatory setting.
    ScopeApplies to members of all ages for Medicare - Wellcare by Fidelis Care.
    Submission requirementSubmit the entire oncology regimen to Evolent (NCH) for review; omissions may result in a denial.
    Submission channelsRequests may be submitted via NCH web portal (my.newcenturyhealth.com) or by phone 1-888-999-7713, option 1. Non-participating providers must submit to the plan via fax 1-844-235-5090.
    Requests that should NOT be submitted to NCH (out-of-scope)
    Do NOT submit to NCH - Antibiotics

    Initial Therapy — Authorization Criteria

    Initial therapy prior review

    Initial authorization requirement

    Initial review: All initial requests for oncology medications and supportive agents listed in this policy (by HCPCS/J/Q code or oral pharmacy codes) must be submitted to Evolent (New Century Health) for review prior to dispensing or administration.

    Includes items regardless of formulary status and applies to both medical and pharmacy benefits; submit the entire oncology regimen to NCH to avoid denial.

    Step Therapy and Preferred Agents

    Drug / ClassPreferred agent(s)Coverage guidance
    Erythropoiesis-stimulating agentsMedical benefit: Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit: ProcritPreferred erythropoiesis-stimulating agents identified; providers should still submit chosen agent to NCH for review prior to dispensing/administration.
    Trastuzumab productsMedical benefit: Trazimera; Pharmacy benefit: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, TrazimeraPreferred trastuzumab biosimilars listed; submit to NCH for review prior to use.
    Bevacizumab productsMedical benefit: Mvasi, Zirabev; Pharmacy benefit: Avastin, Mvasi, ZirabevPreferred bevacizumab biosimilars listed; submit to NCH for review prior to use.
    Hematopoietic agentsMedical & Pharmacy benefit: ZarxioPreferred hematopoietic biosimilar identified; submit to NCH for review prior to use.
    Rituximab productsMedical benefit: Ruxience, Truxima; Pharmacy benefit: Riabni, Rituxan, Rituxan Hycela, Ruxience, TruximaPreferred rituximab biosimilars listed; submit to NCH for review prior to use.
    Bone agentsMedical benefit: zoledronic acid, pamidronate; Pharmacy benefit: zoledronic acid, pamidronate, Prolia, Xgeva, risderonate, ibandronatePreferred bone agents listed; providers should still submit chosen agent to NCH for review prior to administration.
    Prostate cancer agentsMedical benefit: Eligard, Firmagon, Lupron, Trelstar, Vantas, Zoladex (nonpreferred: Provenge); Pharmacy benefit: Trelstar, Lupron, abiraterone acetate (non-preferred: abiraterone acetate micronized)Preferred prostate cancer agents listed; submit to NCH for review prior to use.
    BendamustinePharmacy benefit: BendekaPreferred product for bendamustine identified; submit to NCH for review prior to use.
    AntiemeticsPharmacy benefit: Aprepitant, dronabinol, ondansetron (IV and oral), granisetron (IV and oral), metoclopramide (IV and oral), prochlorperazine (IV and oral), scopolamine patchPreferred antiemetics listed; submit to NCH for review when applicable to oncology supportive care.

    Site of Care — Where Review Applies

    Prior Authorization

    home | office | infusion center | hospital outpatient — review required before dispensing or administration

    Review by NCH is required before dispensing at a pharmacy or before administration in any outpatient setting (home, physician office, infusion center, or hospital outpatient) for participating providers.

    • This requirement applies to members of all ages and to both medical and pharmacy benefit agents listed in the policy.

    Biosimilar Preferences by Agent Class

    Billing Rule

    Erythropoiesis-stimulating agents — preferred agents and notes

    Preferred erythropoiesis-stimulating agents are Retacrit for the medical benefit (with Epogen if Retacrit is unavailable due to shortage) and Procrit for the pharmacy benefit; submit the selected agent to NCH for review.

    • These are preferences only; NCH review is required regardless of agent selected.
    Billing Rule

    Trastuzumab — preferred biosimilars listed

    Preferred trastuzumab biosimilars are identified (medical benefit: Trazimera; pharmacy benefit: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera); submit the chosen product to NCH for review.

    • Preferred list is informational — NCH clinical review is still required for coverage determination.
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Evolent/NCH review)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateDec 1, 2024
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent (NCH) for review prior to dispensing or administration; omissions may result in denial.
    SourceLink
    On This Page
    Coverage Criteria — Prior Authorization RequirementsHCPCS / J / Q Codes and Pharmacy Codes Requiring ReviewWhat Providers Must DoPolicy BackgroundDefinitions and ScopeInitial Therapy — Authorization CriteriaStep Therapy and Preferred AgentsSite of Care — Where Review AppliesBiosimilar Preferences by Agent Class
  1. Trastuzumab: medical Trazimera; pharmacy Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera.
  2. Bevacizumab: medical Mvasi, Zirabev; pharmacy Avastin, Mvasi, Zirabev.
  3. Hematopoietic agents: Zarxio (medical & pharmacy).
  4. Rituximab: medical Ruxience, Truxima; pharmacy Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima.
  5. Documentation Required

    Submission channels and required content

    Submit requests to Evolent (formerly NCH) via the NCH web portal (my.newcenturyhealth.com) or by phone at 1-888-999-7713, option 1; non-participating providers must submit to the plan by fax to 1-844-235-5090.

    • Include the entire oncology regimen when submitting (see complete regimen requirement).
    • Clinical trials may be sent to Evolent for review.
    Denial Risk

    Complete oncology regimen must be submitted

    Submit the entire oncology regimen to Evolent (NCH); omitting any part of the regimen may result in a denial.

    • This requirement applies regardless of prior authorization status for individual agents.
    • Ensure all agents, supportive medications, and schedule details are included in the submission.
    Antibiotic requests are out of scope and should not be submitted to New Century Health.
    Do NOT submit to NCH - Cellular therapies & transplantsBone marrow/stem cell transplants and CAR-T cell therapy requests are out of scope and should not be submitted to NCH.
    Do NOT submit to NCH - Inpatient services and controlled substancesControlled substances, inpatient drug requests, and inpatient radiation/chemotherapy treatments are out of scope and should not be submitted to NCH.
    Do NOT submit to NCH - Diagnostic/other therapiesEquipment requests (infusion pumps), genetic lab testing and laboratory services, radiopharmaceuticals, surgeries/surgical procedures, iron preparations, sickle cell diagnoses and therapies, hemophilia drugs, and immune globulins are out of scope and should not be submitted to NCH.
    Billing Rule

    Bevacizumab — preferred biosimilars listed

    Preferred bevacizumab biosimilars are listed (medical benefit: Mvasi, Zirabev; pharmacy benefit: Avastin, Mvasi, Zirabev); providers must still submit the selected product to NCH for review.

    • Selection of a preferred biosimilar does not replace the requirement for NCH review prior to dispensing/administration.
    Billing Rule

    Hematopoietic agents — preferred biosimilar guidance

    Preferred hematopoietic agent biosimilar is Zarxio (medical & pharmacy benefit); submit the agent to NCH for review.

    • This is a preference; NCH review remains required for authorization.
    Billing Rule

    Rituximab — preferred biosimilars listed

    Preferred rituximab biosimilars are identified for medical and pharmacy benefit (medical: Ruxience, Truxima; pharmacy: Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima); providers must submit the chosen rituximab product to NCH for review.

    • Preferred lists are informational — NCH clinical review is still required prior to dispensing/administration.